Does CABOZANTINIB S-MALATE Cause Hepatocellular carcinoma? 219 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 219 reports of Hepatocellular carcinoma have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 0.6% of all adverse event reports for CABOZANTINIB S-MALATE.
219
Reports of Hepatocellular carcinoma with CABOZANTINIB S-MALATE
0.6%
of all CABOZANTINIB S-MALATE reports
72
Deaths
27
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From CABOZANTINIB S-MALATE?
Of the 219 reports, 72 (32.9%) resulted in death, 27 (12.3%) required hospitalization, and 2 (0.9%) were considered life-threatening.
Is Hepatocellular carcinoma Listed in the Official Label?
Yes, Hepatocellular carcinoma is listed as a known adverse reaction in the official FDA drug label for CABOZANTINIB S-MALATE.
What Other Side Effects Does CABOZANTINIB S-MALATE Cause?
Diarrhoea (8,282)
Fatigue (6,819)
Off label use (5,245)
Nausea (4,341)
Decreased appetite (4,076)
Blood pressure increased (2,939)
Malignant neoplasm progression (2,718)
Palmar-plantar erythrodysaesthesia syndrome (2,706)
Weight decreased (2,657)
Stomatitis (2,560)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
TACROLIMUS (183)
SOFOSBUVIR\VELPATASVIR (161)
Which CABOZANTINIB S-MALATE Alternatives Have Lower Hepatocellular carcinoma Risk?
CABOZANTINIB S-MALATE vs CAFFEINE
CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL
CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL
CABOZANTINIB S-MALATE vs CALCIFEDIOL
CABOZANTINIB S-MALATE vs CALCIPOTRIENE